The United Kingdom remains one of the most scientifically advanced and globally recognized locations for clinical trials. With a strong academic ecosystem, centralized healthcare system, and globally respected regulatory authority, the UK continues to play a critical role in early-phase and innovative clinical trials.
For sponsors planning clinical programmes in the United Kingdom, understanding the post-Brexit regulatory environment, national requirements, and operational landscape is essential to ensuring efficient study execution.
| Metric | UK |
| Competent Authority | MHRA |
| Ethics Committees | RECs |
| Approval Timeline | ~60 days |
| Population | ~69 million |
| Strengths | Oncology, rare diseases, CNS, advanced therapies |
Sponsors conduct clinical trials in the UK due to its strong scientific foundation and leadership in innovative research.
Key advantages include:
The United Kingdom is particularly attractive for complex and innovation-driven clinical trials requiring scientific depth and specialized expertise.
Clinical trials in the United Kingdom are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Following Brexit, the UK operates under its own national regulatory framework, separate from the European Union Clinical Trials Regulation (CTIS system).
Key components include:
The UK has implemented a combined review pathway, allowing regulatory and ethics submissions to be assessed in parallel, improving efficiency.
Sponsors planning to run clinical trials in the UK must submit applications through national systems rather than CTIS.
Required documentation includes:
The UK’s combined review process enables simultaneous evaluation by MHRA and ethics committees, reducing administrative complexity.
Approval timelines in the UK are competitive, particularly with the combined review system.
| Step | Estimated Timeline |
|---|---|
| Submission | Day 0 |
| Validation | ~7 days |
| Combined review (MHRA + REC) | ~30–60 days |
| Final authorization | ~60 days |
The UK is considered one of the faster countries in Europe for clinical trial approvals, particularly for early-phase studies.
Brexit has introduced important changes that sponsors must consider when conducting clinical trials in the UK.
Key changes include:
However, the UK has also introduced improvements:
For sponsors, this means that while the UK adds regulatory complexity in multinational trials, it can also offer greater speed and flexibility when managed correctly.
Sponsors conducting clinical trials in the UK must comply with several country-specific requirements.
Key considerations include:
QP release is particularly important for ensuring that IMPs meet UK regulatory requirements before use in clinical trials.
The UK offers a highly organized clinical research infrastructure supported by the National Health Service.
Key strengths include:
This infrastructure supports both early-phase innovation and large-scale clinical trials.
The UK provides access to a large patient population through the NHS, with strong capabilities in specific therapeutic areas.
Advantages include:
However, recruitment speed can vary depending on:
Sponsors often combine the UK with other countries to optimize recruitment timelines.
The UK is particularly strong in:
The UK is frequently selected for scientifically complex and innovative clinical trials.
Operational timelines in the UK are competitive, particularly when leveraging national infrastructure.
| Stage | Estimated Timeline |
|---|---|
| Regulatory and ethics approval | ~60 days |
| Site selection and contracting | 1–2 months |
| Site activation | 2–3 months |
| First patient in (FPI) | 3–4 months |
The UK is well suited for sponsors aiming for efficient start-up combined with high-quality execution.
The UK is considered a mid-to-high cost country for clinical trials.
Cost considerations include:
Sponsors often accept higher upfront costs in exchange for scientific expertise and regulatory efficiency.
The UK is particularly well suited for:
Sponsors benefit from the UK’s scientific leadership and regulatory flexibility.
While the UK offers strong scientific capabilities, it may not always provide sufficient recruitment on its own.
Sponsors often combine the UK with European countries to:
A dual UK–EU strategy is common in multinational clinical trials.
Clinical trials in the UK offer several key advantages:
These factors position the UK as a leading destination for clinical trials globally.
Running clinical trials in the UK requires navigating both regulatory independence and operational complexity following Brexit.
APICES CRO supports sponsors by:
By integrating the United Kingdom expertise within a broader European strategy, APICES helps sponsors run clinical trials with greater efficiency and alignment.
How long does it take to get approval for a clinical trial in the UK?
Approval typically takes around 60 days using the combined MHRA and ethics review process.
Does the UK use CTIS?
No, the UK operates its own regulatory system following Brexit.
What is QP release in the UK?
QP release ensures that investigational medicinal products meet regulatory requirements before use in clinical trials.
Is the UK suitable for early-phase clinical trials?
Yes, the UK is one of the leading countries for early-phase and first-in-human studies.
Do sponsors need separate submissions for UK and EU trials?
Yes, multinational trials often require separate regulatory submissions for the UK and EU.
Is the UK good for patient recruitment?
The UK provides access to well-characterized patients, but recruitment may be complemented by other countries in multinational trials.
How does the UK clinical-trial regulatory process work post-Brexit?
The UK is no longer in CTIS. The MHRA (Medicines and Healthcare products Regulatory Agency) operates a Combined Review with the HRA Research Ethics Committee, with a single application portal. Standard review is 30 calendar days; the MHRA Notification Scheme can speed certain low-risk trials.
Should I include the UK alongside an EU CTR submission?
For studies where UK recruitment matters, yes — the UK adds substantial site capacity, particularly in oncology, hematology, and rare disease. The submissions are independent (CTIS for the EU, IRAS for the UK), so plan parallel preparation rather than sequential.
Why do sponsors choose the UK for oncology?
The NIHR-funded site network (Cambridge, London, Manchester, Birmingham, Edinburgh, Glasgow), strong investigator-led research culture, and the UK Cancer Research Network give access to high-volume oncology sites. The Innovative Licensing and Access Pathway (ILAP) is also relevant for some sponsors.
What is the typical start-up timeline in the UK?
Under Combined Review, plan 4–6 months from final protocol to first-patient-in for a single-country UK oncology Phase II trial. Site contracting has historically been the slowest step; the new model agreements (mCTA) help.
What are typical per-patient costs in the UK?
Fees-per-patient typically run £18,000–£40,000 for Phase II oncology, plus NHS overhead.
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
